1. Phylogeny:  
   MAPK9, commonly known as JNK2, is a member of the c‐Jun N‐terminal kinase (JNK) subgroup within the larger mitogen‐activated protein kinase (MAPK) family and is highly conserved across eukaryotes (bogoyevitch2006usesforjnk pages 1-2, Manning2002Protein).  
   JNK2 shares a high degree of sequence identity with its paralogs JNK1 and JNK3, and it belongs to the CMGC group of kinases that includes cyclin‐dependent kinases (CDKs), glycogen synthase kinases (GSKs), and other stress‐responsive kinases (bogoyevitch2006usesforjnk pages 2-3, Manning2002Evolution).  
   Orthologs of MAPK9 exist in other mammalian species, and its conservation extends to other vertebrates, placing it within an evolutionary core set of MAP kinases that originated in the Last Eukaryotic Common Ancestor (LECA) (bogoyevitch2006usesforjnk pages 1-2, Manning2002Protein).  
   Phylogenetic reconstructions indicate that the JNK group diverged from the other MAPK subfamilies early in evolution, and its relatedness to other stress-activated kinases emphasizes both its functional specialization and the common ancestry shared by the MAPK superfamily (bogoyevitch2006usesforjnk pages 2-3, Manning2002Evolution).
2. Reaction Catalyzed:  
   MAPK9 catalyzes the transfer of a phosphate group from ATP to the hydroxyl group of serine or threonine residues on target proteins, thereby converting ATP to ADP and producing a phosphorylated substrate along with a proton (bogoyevitch2006usesforjnk pages 1-2, pearson2001mitogenactivatedprotein(map) pages 1-2).  
   The general chemical reaction is: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺ (bogoyevitch2006usesforjnk pages 1-2).
3. Cofactor Requirements:  
   The catalytic activity of MAPK9 is dependent on the presence of divalent metal ions, with Mg²⁺ being required for optimal kinase function (bogoyevitch2006usesforjnk pages 1-2, pearson2001mitogenactivatedprotein(map) pages 1-2).  
   This requirement is shared by nearly all protein kinases, which utilize Mg²⁺ as a cofactor to facilitate ATP binding and phosphoryl transfer (cuschieri2005mitogenactivatedproteinkinase pages 1-2).
4. Substrate Specificity:  
   MAPK9 displays substrate specificity that is characteristic of proline-directed serine/threonine kinases, preferentially phosphorylating substrates containing a serine or threonine residue immediately followed by a proline residue, commonly referred to as the S/T-P motif (bogoyevitch2006usesforjnk pages 1-2, bogoyevitch2006usesforjnk pages 9-10).  
   In addition to the minimal S/T-P motif, substrate recognition is further enhanced by docking interactions; many substrates possess specific docking domains, such as D-motifs, which interact with complementary binding grooves on MAPK9 and contribute to its high degree of substrate specificity (bogoyevitch2006usesforjnk pages 4-6, yasuda1999thejipgroup pages 1-2).  
   Recent analyses of the substrate specificity landscape for serine/threonine kinases, as reported by Johnson et al. (2023), support that MAPK9 prefers substrates with flanking basic residues and hydrophobic features surrounding the S/T-P core (Johnson2023Atlas).
5. Structure:  
   The three-dimensional structure of MAPK9 is characterized by a conserved bilobal kinase fold consisting of a smaller N-terminal lobe mainly composed of β-sheets and a larger C-terminal lobe enriched in α-helices, with the ATP-binding cleft located at their interface (bogoyevitch2006usesforjnk pages 2-3, chen2011mapk9(mitogenactivatedprotein pages 1-2).  
   A key structural element is the activation loop, which contains the conserved Thr-Pro-Tyr (TPY) motif whose dual phosphorylation is essential for inducing conformational changes that enable substrate access and catalytic activity (bogoyevitch2006usesforjnk pages 2-3, wada2004mitogenactivatedproteinkinases pages 1-2).  
   MAPK9 also possesses a docking groove formed by residues on the kinase surface that interacts with D-motifs on substrates and scaffold proteins, thereby facilitating efficient substrate recruitment (bogoyevitch2006usesforjnk pages 4-6, bogoyevitch2006usesforjnk pages 7-9).  
   The catalytic core includes a glycine-rich loop important for ATP binding, a well-conserved catalytic loop with a key aspartic acid residue required for phosphoryl transfer, and a C-helix whose positioning is critical for the regulation of enzyme activity (niu2007kineticcharacterizationof pages 1-2, pearson2001mitogenactivatedprotein(map) pages 5-6).  
   Structural studies, including those using crystallographic and AlphaFold models, reveal that while the overall fold is conserved with other MAP kinases, subtle conformational variations in the docking site and activation loop may underlie isoform-specific substrate recognition and kinetics (bogoyevitch2006usesforjnk pages 7-9, niu2007kineticcharacterizationof pages 8-9).
6. Regulation:  
   The regulatory mechanisms governing MAPK9 activity are multifaceted, centering on its activation by dual phosphorylation of the TPY motif within the activation loop by the upstream dual-specificity kinases MAP2K4 (MKK4) and MAP2K7 (MKK7) (bogoyevitch2006usesforjnk pages 2-3, cuschieri2005mitogenactivatedproteinkinase pages 1-2).  
   This dual phosphorylation event induces a conformational change that enhances the accessibility of the catalytic site and enables efficient substrate binding and catalysis (bogoyevitch2006usesforjnk pages 4-6, wada2004mitogenactivatedproteinkinases pages 1-2).  
   Regulation is further modulated by scaffold proteins such as JIP1, which organize MAPK modules by binding MAPK9 along with its upstream activators and substrates, thereby increasing the specificity and efficiency of signal transduction (yasuda1999thejipgroup pages 1-2, bogoyevitch2006usesforjnk pages 28-29).  
   Furthermore, post-translational modifications beyond phosphorylation, including ubiquitination and sumoylation of interacting partners, can influence the stability and activity of MAPK9 indirectly by affecting scaffold assembly and substrate availability (chen2011mapk9(mitogenactivatedprotein pages 1-2, bogoyevitch2006usesforjnk pages 20-22).  
   Experimental evidence using specific inhibitors such as SP600125 demonstrates that inhibition of MAPK9 activity leads to decreased phosphorylation of key downstream substrates, confirming its role in mediating stress responses (stebbins2008identificationofa pages 1-2, hammaker2004regulationofcjun pages 1-2).
7. Function:  
   MAPK9 plays a pivotal role in the regulation of diverse cellular processes including cell proliferation, differentiation, migration, transformation, and programmed cell death (apoptosis) by modulating the activity of multiple transcription factors and other regulatory proteins (bogoyevitch2006usesforjnk pages 1-2, chen2011mapk9(mitogenactivatedprotein pages 1-2).  
   A major function of MAPK9 is the phosphorylation of components of the AP-1 transcription factor complex, such as c-Jun and ATF2, leading to altered gene expression in response to extracellular stress stimuli including pro-inflammatory cytokines, UV irradiation, and osmotic stress (bogoyevitch2006usesforjnk pages 1-2, bogoyevitch2006usesforjnk pages 26-27).  
   In addition, MAPK9 is involved in the cellular response to oxidative and ribotoxic stress by phosphorylating the RNA polymerase I-specific transcription initiation factor RRN3, thereby inhibiting rRNA synthesis (chen2011mapk9(mitogenactivatedprotein pages 1-2, bogoyevitch2006usesforjnk pages 2-3).  
   MAPK9 promotes apoptosis under stress conditions by phosphorylating key regulatory factors such as TP53 and YAP1, and it also plays an essential role in T-cell receptor signaling that is critical for the polarization of T-helper cells towards a Th1 phenotype (bogoyevitch2006usesforjnk pages 20-22, hammaker2004regulationofcjun pages 1-2).  
   Additional functional roles of MAPK9 include the regulation of epithelial tight junctions in response to osmotic stress, promotion of beta-catenin degradation leading to inhibition of canonical Wnt signaling, and modulation of circadian rhythms through phosphorylation of the CLOCK-BMAL1 heterodimer (bogoyevitch2006usesforjnk pages 1-2, hammaker2004regulationofcjun pages 6-7).  
   Moreover, by phosphorylating transcription factors such as POU5F1 (OCT4) and ALKBH5, MAPK9 influences stem cell maintenance and the cellular response to reactive oxygen species, respectively, thereby impacting cell fate decisions and stress adaptation (bogoyevitch2006usesforjnk pages 20-22, chen2011mapk9(mitogenactivatedprotein pages 1-2).
8. Other Comments:  
   MAPK9 is a target of considerable pharmacological interest, and several small molecule inhibitors, most notably SP600125, have been used in experimental settings to attenuate its activity in disease models such as rheumatoid arthritis, cancer, and neurodegenerative disorders (stebbins2008identificationofa pages 1-2, hammaker2004regulationofcjun pages 1-2).  
   Dysregulation of MAPK9 signaling has been associated with a variety of pathological conditions, including inflammatory diseases, metabolic disorders such as insulin resistance, and certain cancers, highlighting its significance as a therapeutic target (bogoyevitch2006usesforjnk pages 1-2, pritchard2013molecularpathwaysmitogenactivated pages 2-3).  
   No single inhibitor exhibits absolute specificity for MAPK9, and current compounds often display off-target effects; therefore, ongoing efforts are aimed at developing more selective inhibitors that can modulate MAPK9 activity with minimal interference in related MAPK families (stebbins2008identificationofa pages 1-2, wada2004mitogenactivatedproteinkinases pages 1-2).  
   Notable disease mutations specifically affecting MAPK9 have not been widely reported, but alterations in upstream regulatory components of the JNK signaling cascade may indirectly impact its function in pathological states (bogoyevitch2006usesforjnk pages 2-3, hammaker2004regulationofcjun pages 6-7).
9. References:
10. bogoyevitch2006usesforjnk pages 1-2
11. bogoyevitch2006usesforjnk pages 2-3
12. bogoyevitch2006usesforjnk pages 4-6
13. bogoyevitch2006usesforjnk pages 6-7
14. bogoyevitch2006usesforjnk pages 7-9
15. bogoyevitch2006usesforjnk pages 9-10
16. bogoyevitch2006usesforjnk pages 20-22
17. bogoyevitch2006usesforjnk pages 25-26
18. bogoyevitch2006usesforjnk pages 26-27
19. bogoyevitch2006usesforjnk pages 27-28
20. bogoyevitch2006usesforjnk pages 28-29
21. bogoyevitch2006usesforjnk pages 30-31
22. bogoyevitch2006usesforjnk pages 32-33
23. bogoyevitch2006usesforjnk pages 35-35
24. chen2011mapk9(mitogenactivatedprotein pages 1-2
25. chen2011mapk9(mitogenactivatedprotein pages 2-2
26. chu1996themitogenactivatedprotein pages 1-1
27. cuschieri2005mitogenactivatedproteinkinase pages 1-2
28. girnius2018thecjunnh2terminal pages 23-28
29. hammaker2004regulationofcjun pages 1-2
30. hammaker2004regulationofcjun pages 5-6
31. hammaker2004regulationofcjun pages 6-7
32. niu2007kineticcharacterizationof pages 1-2
33. niu2007kineticcharacterizationof pages 8-9
34. niu2007kineticcharacterizationof pages 9-9
35. pearson2001mitogenactivatedprotein(map) pages 1-2
36. pearson2001mitogenactivatedprotein(map) pages 5-6
37. pearson2001mitogenactivatedprotein(map) pages 12-12
38. pearson2001mitogenactivatedprotein(map) pages 13-15
39. pearson2001mitogenactivatedprotein(map) pages 2-3
40. pearson2001mitogenactivatedprotein(map) pages 20-21
41. pearson2001mitogenactivatedprotein(map) pages 24-24
42. pritchard2013molecularpathwaysmitogenactivated pages 2-3
43. raman2007differentialregulationand pages 4-5
44. raman2007differentialregulationand pages 5-6
45. raman2007differentialregulationand pages 6-7
46. sugden1998“stressresponsive”mitogenactivatedprotein pages 1-2
47. wada2004mitogenactivatedproteinkinases pages 1-2
48. wada2004mitogenactivatedproteinkinases pages 2-3
49. wada2004mitogenactivatedproteinkinases pages 3-4
50. wada2004mitogenactivatedproteinkinases pages 8-9
51. widmann1999mitogenactivatedproteinkinase pages 21-22
52. widmann1999mitogenactivatedproteinkinase pages 3-4
53. yasuda1999thejipgroup pages 1-2
54. figueralosada2012enzymekineticsand pages 11-12
55. kyriakis2001mammalianmitogenactivatedprotein pages 13-15
56. li2011evolutionaryhistoryof pages 11-12
57. Manning2002Protein
58. Manning2002Evolution
59. Johnson2023Atlas

References

1. (bogoyevitch2006usesforjnk pages 1-2): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
2. (bogoyevitch2006usesforjnk pages 2-3): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
3. (bogoyevitch2006usesforjnk pages 20-22): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
4. (bogoyevitch2006usesforjnk pages 4-6): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
5. (cuschieri2005mitogenactivatedproteinkinase pages 1-2): Joseph Cuschieri and Ronald V. Maier. Mitogen-activated protein kinase (mapk). Critical Care Medicine, 33:S417-S419, Dec 2005. URL: https://doi.org/10.1097/01.ccm.0000191714.39495.a6, doi:10.1097/01.ccm.0000191714.39495.a6. This article has 143 citations and is from a domain leading peer-reviewed journal.
6. (girnius2018thecjunnh2terminal pages 23-28): Nomeda Girnius. The cjun nh2-terminal kinase pathway in mammary gland biology and carcinogenesis. Unknown journal, 2018. URL: https://doi.org/10.13028/m2fh6m, doi:10.13028/m2fh6m. This article has 0 citations.
7. (niu2007kineticcharacterizationof pages 1-2): Linghao Niu, Kung-Ching Chang, Stacy Wilson, Patricia Tran, Fengrong Zuo, and David C. Swinney. Kinetic characterization of human jnk2alpha2 reaction mechanism using substrate competitive inhibitors. Biochemistry, 46 16:4775-84, Apr 2007. URL: https://doi.org/10.1021/bi602423e, doi:10.1021/bi602423e. This article has 30 citations and is from a peer-reviewed journal.
8. (niu2007kineticcharacterizationof pages 8-9): Linghao Niu, Kung-Ching Chang, Stacy Wilson, Patricia Tran, Fengrong Zuo, and David C. Swinney. Kinetic characterization of human jnk2alpha2 reaction mechanism using substrate competitive inhibitors. Biochemistry, 46 16:4775-84, Apr 2007. URL: https://doi.org/10.1021/bi602423e, doi:10.1021/bi602423e. This article has 30 citations and is from a peer-reviewed journal.
9. (stebbins2008identificationofa pages 1-2): John L. Stebbins, Surya K. De, Thomas Machleidt, Barbara Becattini, Jesus Vazquez, Christian Kuntzen, Li-Hsing Chen, Jason F. Cellitti, Megan Riel-Mehan, Aras Emdadi, Giovanni Solinas, Michael Karin, and Maurizio Pellecchia. Identification of a new jnk inhibitor targeting the jnk-jip interaction site. Proceedings of the National Academy of Sciences, 105:16809-16813, Oct 2008. URL: https://doi.org/10.1073/pnas.0805677105, doi:10.1073/pnas.0805677105. This article has 232 citations.
10. (bogoyevitch2006usesforjnk pages 25-26): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
11. (bogoyevitch2006usesforjnk pages 26-27): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
12. (bogoyevitch2006usesforjnk pages 27-28): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
13. (bogoyevitch2006usesforjnk pages 28-29): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
14. (bogoyevitch2006usesforjnk pages 32-33): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
15. (bogoyevitch2006usesforjnk pages 6-7): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
16. (bogoyevitch2006usesforjnk pages 7-9): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
17. (chen2011mapk9(mitogenactivatedprotein pages 1-2): F Chen. Mapk9 (mitogen-activated protein kinase 9). Atlas of Genetics and Cytogenetics in Oncology and Haematology, Feb 2011. URL: https://doi.org/10.4267/2042/37950, doi:10.4267/2042/37950. This article has 1 citations and is from a peer-reviewed journal.
18. (chen2011mapk9(mitogenactivatedprotein pages 2-2): F Chen. Mapk9 (mitogen-activated protein kinase 9). Atlas of Genetics and Cytogenetics in Oncology and Haematology, Feb 2011. URL: https://doi.org/10.4267/2042/37950, doi:10.4267/2042/37950. This article has 1 citations and is from a peer-reviewed journal.
19. (chu1996themitogenactivatedprotein pages 1-1): Yanfang Chu, Patricia A. Solski, Roya Khosravi-Far, Channing J. Der, and Kathleen Kelly. The mitogen-activated protein kinase phosphatases pac1, mkp-1, and mkp-2 have unique substrate specificities and reduced activity in vivo toward the erk2 sevenmaker mutation. Journal of Biological Chemistry, 271:6497-6501, Mar 1996. URL: https://doi.org/10.1074/jbc.271.11.6497, doi:10.1074/jbc.271.11.6497. This article has 555 citations and is from a domain leading peer-reviewed journal.
20. (niu2007kineticcharacterizationof pages 9-9): Linghao Niu, Kung-Ching Chang, Stacy Wilson, Patricia Tran, Fengrong Zuo, and David C. Swinney. Kinetic characterization of human jnk2alpha2 reaction mechanism using substrate competitive inhibitors. Biochemistry, 46 16:4775-84, Apr 2007. URL: https://doi.org/10.1021/bi602423e, doi:10.1021/bi602423e. This article has 30 citations and is from a peer-reviewed journal.
21. (pearson2001mitogenactivatedprotein(map) pages 1-2): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
22. (pearson2001mitogenactivatedprotein(map) pages 12-12): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
23. (pearson2001mitogenactivatedprotein(map) pages 5-6): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
24. (pritchard2013molecularpathwaysmitogenactivated pages 2-3): Antonia L. Pritchard and Nicholas K. Hayward. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clinical Cancer Research, 19:2301-2309, Apr 2013. URL: https://doi.org/10.1158/1078-0432.ccr-12-0383, doi:10.1158/1078-0432.ccr-12-0383. This article has 124 citations and is from a highest quality peer-reviewed journal.
25. (raman2007differentialregulationand pages 4-5): Malavika Raman, Wei Chen, and M. Cobb. Differential regulation and properties of mapks. Oncogene, 26:3100-3112, May 2007. URL: https://doi.org/10.1038/sj.onc.1210392, doi:10.1038/sj.onc.1210392. This article has 1953 citations and is from a domain leading peer-reviewed journal.
26. (raman2007differentialregulationand pages 6-7): Malavika Raman, Wei Chen, and M. Cobb. Differential regulation and properties of mapks. Oncogene, 26:3100-3112, May 2007. URL: https://doi.org/10.1038/sj.onc.1210392, doi:10.1038/sj.onc.1210392. This article has 1953 citations and is from a domain leading peer-reviewed journal.
27. (sugden1998“stressresponsive”mitogenactivatedprotein pages 1-2): Peter H. Sugden and Angela Clerk. “stress-responsive” mitogen-activated protein kinases (c-jun n-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circulation Research, 83:345-352, Aug 1998. URL: https://doi.org/10.1161/01.res.83.4.345, doi:10.1161/01.res.83.4.345. This article has 690 citations and is from a highest quality peer-reviewed journal.
28. (wada2004mitogenactivatedproteinkinases pages 1-2): Teiji Wada and Josef M Penninger. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 23:2838-2849, Apr 2004. URL: https://doi.org/10.1038/sj.onc.1207556, doi:10.1038/sj.onc.1207556. This article has 1895 citations and is from a domain leading peer-reviewed journal.
29. (wada2004mitogenactivatedproteinkinases pages 2-3): Teiji Wada and Josef M Penninger. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 23:2838-2849, Apr 2004. URL: https://doi.org/10.1038/sj.onc.1207556, doi:10.1038/sj.onc.1207556. This article has 1895 citations and is from a domain leading peer-reviewed journal.
30. (widmann1999mitogenactivatedproteinkinase pages 21-22): CHRISTIAN WIDMANN, SPENCER GIBSON, MATTHEW B. JARPE, and GARY L. JOHNSON. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiological Reviews, 79:143-180, Jan 1999. URL: https://doi.org/10.1152/physrev.1999.79.1.143, doi:10.1152/physrev.1999.79.1.143. This article has 3790 citations and is from a highest quality peer-reviewed journal.
31. (widmann1999mitogenactivatedproteinkinase pages 3-4): CHRISTIAN WIDMANN, SPENCER GIBSON, MATTHEW B. JARPE, and GARY L. JOHNSON. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiological Reviews, 79:143-180, Jan 1999. URL: https://doi.org/10.1152/physrev.1999.79.1.143, doi:10.1152/physrev.1999.79.1.143. This article has 3790 citations and is from a highest quality peer-reviewed journal.
32. (yasuda1999thejipgroup pages 1-2): Jun Yasuda, Alan J. Whitmarsh, Julie Cavanagh, Manoj Sharma, and Roger J. Davis. The jip group of mitogen-activated protein kinase scaffold proteins. Molecular and Cellular Biology, 19:7245-7254, Oct 1999. URL: https://doi.org/10.1128/mcb.19.10.7245, doi:10.1128/mcb.19.10.7245. This article has 649 citations and is from a domain leading peer-reviewed journal.
33. (bogoyevitch2006usesforjnk pages 30-31): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
34. (bogoyevitch2006usesforjnk pages 35-35): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
35. (bogoyevitch2006usesforjnk pages 9-10): Marie A. Bogoyevitch and Bostjan Kobe. Uses for jnk: the many and varied substrates of the c-jun n-terminal kinases. Microbiology and Molecular Biology Reviews, 70:1061-1095, Dec 2006. URL: https://doi.org/10.1128/mmbr.00025-06, doi:10.1128/mmbr.00025-06. This article has 788 citations and is from a domain leading peer-reviewed journal.
36. (figueralosada2012enzymekineticsand pages 11-12): Mariana Figuera-Losada and Philip V. LoGrasso. Enzyme kinetics and interaction studies for human jnk1β1 and substrates activating transcription factor 2 (atf2) and c-jun n-terminal kinase (c-jun). Journal of Biological Chemistry, 287:13291-13302, Apr 2012. URL: https://doi.org/10.1074/jbc.m111.323766, doi:10.1074/jbc.m111.323766. This article has 32 citations and is from a domain leading peer-reviewed journal.
37. (hammaker2004regulationofcjun pages 1-2): Deepa R. Hammaker, David L. Boyle, Martine Chabaud-Riou, and Gary S. Firestein. Regulation of c-jun n-terminal kinase by mekk-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. The Journal of Immunology, 172:1612-1618, Feb 2004. URL: https://doi.org/10.4049/jimmunol.172.3.1612, doi:10.4049/jimmunol.172.3.1612. This article has 110 citations.
38. (hammaker2004regulationofcjun pages 5-6): Deepa R. Hammaker, David L. Boyle, Martine Chabaud-Riou, and Gary S. Firestein. Regulation of c-jun n-terminal kinase by mekk-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. The Journal of Immunology, 172:1612-1618, Feb 2004. URL: https://doi.org/10.4049/jimmunol.172.3.1612, doi:10.4049/jimmunol.172.3.1612. This article has 110 citations.
39. (hammaker2004regulationofcjun pages 6-7): Deepa R. Hammaker, David L. Boyle, Martine Chabaud-Riou, and Gary S. Firestein. Regulation of c-jun n-terminal kinase by mekk-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. The Journal of Immunology, 172:1612-1618, Feb 2004. URL: https://doi.org/10.4049/jimmunol.172.3.1612, doi:10.4049/jimmunol.172.3.1612. This article has 110 citations.
40. (kyriakis2001mammalianmitogenactivatedprotein pages 13-15): John M. Kyriakis and Joseph Avruch. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiological Reviews, 81:807-869, Apr 2001. URL: https://doi.org/10.1152/physrev.2001.81.2.807, doi:10.1152/physrev.2001.81.2.807. This article has 4483 citations and is from a highest quality peer-reviewed journal.
41. (li2011evolutionaryhistoryof pages 11-12): Meng Li, Jun Liu, and Chiyu Zhang. Evolutionary history of the vertebrate mitogen activated protein kinases family. PLoS ONE, 6:e26999, Oct 2011. URL: https://doi.org/10.1371/journal.pone.0026999, doi:10.1371/journal.pone.0026999. This article has 96 citations and is from a peer-reviewed journal.
42. (pearson2001mitogenactivatedprotein(map) pages 13-15): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
43. (pearson2001mitogenactivatedprotein(map) pages 2-3): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
44. (pearson2001mitogenactivatedprotein(map) pages 20-21): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
45. (pearson2001mitogenactivatedprotein(map) pages 24-24): G. Pearson, Fred L Robinson, T. Gibson, Bing-e Xu, M. Karandikar, K. Berman, and M. Cobb. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22:153-183, Apr 2001. URL: https://doi.org/10.1210/er.22.2.153, doi:10.1210/er.22.2.153. This article has 5923 citations and is from a domain leading peer-reviewed journal.
46. (raman2007differentialregulationand pages 5-6): Malavika Raman, Wei Chen, and M. Cobb. Differential regulation and properties of mapks. Oncogene, 26:3100-3112, May 2007. URL: https://doi.org/10.1038/sj.onc.1210392, doi:10.1038/sj.onc.1210392. This article has 1953 citations and is from a domain leading peer-reviewed journal.
47. (wada2004mitogenactivatedproteinkinases pages 3-4): Teiji Wada and Josef M Penninger. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 23:2838-2849, Apr 2004. URL: https://doi.org/10.1038/sj.onc.1207556, doi:10.1038/sj.onc.1207556. This article has 1895 citations and is from a domain leading peer-reviewed journal.
48. (wada2004mitogenactivatedproteinkinases pages 8-9): Teiji Wada and Josef M Penninger. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 23:2838-2849, Apr 2004. URL: https://doi.org/10.1038/sj.onc.1207556, doi:10.1038/sj.onc.1207556. This article has 1895 citations and is from a domain leading peer-reviewed journal.